Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

Core Viewpoint - Novartis is set to acquire Excellergy, Inc. to enhance its immunology strategy, particularly in food allergies and other IgE-driven diseases, with the lead asset Exl-111 showing promise in improving symptom control and convenience [1][2][3] Group 1: Acquisition Details - Novartis will pay up to USD 2 billion in upfront and milestone payments for the acquisition of Excellergy, with the transaction expected to close in the second half of 2026, pending regulatory approvals [4] Group 2: Product and Mechanism - Exl-111 is a half-life extended, high-affinity anti-IgE antibody currently in Phase 1, designed to dissociate receptor-bound IgE and achieve faster, deeper pathway suppression compared to conventional therapies [1][3] - The acquisition builds on Novartis's established expertise in IgE biology and aims to complement its existing allergy portfolio across various allergic conditions [2][3] Group 3: Strategic Importance - The proposed acquisition reflects Novartis's commitment to advancing innovative science to provide meaningful benefits to patients suffering from allergic diseases [3] - Exl-111 has the potential to support earlier symptom relief and broader use in conditions such as food allergies, chronic spontaneous urticaria, and allergic asthma, including pediatric populations [3]